

Bayer HealthCare



0588 '03 FEB 13 P3:25

Allen H. Heller, M.D.  
Head of Global  
Research & Development

February 11, 2003

Dockets Management Branch  
Food and Drug Administration  
Department of Health and Human Services  
Room 1-23  
12420 Parklawn Drive  
Rockville, Maryland 20857

Docket: 77N-0094  
FDA Rulemaking on Professional Labeling for Aspirin

CITIZEN PETITION

The undersigned submits this petition under 21 CFR 330.10 to request the Commissioner of Food and Drugs to amend the Final Rule for Professional Labeling for Aspirin to include the use of 75mg-325mg aspirin for the primary prevention of myocardial infarction in those individuals at sufficient risk.

Bayer HealthCare LLC  
36 Columbia Road  
P.O. Box 1910  
Morristown, NJ 07962-1910  
Phone: 973 408-8015  
Fax: 973 254-4856  
allen.heller@bayer.com

This request is supported by the submission of five landmark primary prevention trials:

- Physician's Health Study (1988)
- British Doctors' Trial (1988)
- Thrombosis Prevention Trial (1998)
- Hypertensive Optimal Treatment Study (1998)
- Primary Prevention Project (2001)

The Citizen's Petition summarizes the results of five major clinical trials in primary prevention, involving over 55,000 subjects. These trials demonstrate in the aggregate that aspirin significantly reduces the risk of a first non-fatal MI by 32%. Based on an independent review of these trials, the American Heart Association (AHA) and the U.S. Preventive Services Task Force (USPSTF) published guidelines within the last year recommending that patients with sufficient risk of a first MI be considered for aspirin therapy. The proposed labeling revision is based on the AHA guidelines. The AHA recommends that individuals with a 10-year risk equal to or greater than 10% be evaluated for treatment with aspirin as the benefits outweigh the risks.


77N-0094

CP 16

Bayer looks forward to working closely with the Agency to facilitate the prompt approval of this new indication for aspirin. We believe that your approval of this indication will help to improve the health and welfare of millions of Americans.

Please contact me at 973-408-8015 or Judy Doyle at 973-408-8181 with questions regarding this submission.

Bayer Healthcare  
Consumer Care Division



Allen H. Heller, M.D.  
Head of Global Research and Development

**Charles H. Hennekens, MD, Dr. PH**  
Visiting Professor of Medicine &  
Epidemiology and Public Health  
University of Miami School of Medicine  
Director of Cardiovascular Research



*Mailing Address:*  
2800 S. Ocean Blvd, PH-A  
Boca Raton, FL 33432 USA  
*Phone & Fax.* (561) 393-8845  
*E-Mail* PROFCHHMD@prodigy.net

February 11, 2003

Douglas Throckmorton, MD  
Chief, Division of Cardiorenal Drugs  
Food and Drug Administration  
1451 Rockville Pike  
Document Control Room, HFD110  
Rockville, MD 20852

Dear Dr. Throckmorton

About 10 years ago I collaborated with Bayer on their submission of two Citizen's Petitions for the professional labeling of aspirin, which led to actions by the US Food and Drug Administration (FDA). The first concerned a new indication for acute myocardial infarction (MI) and the second was an expansion of the indications for secondary prevention of cardiovascular events.

At this time I have again collaborated with Bayer and, in particular, at the invitation of Allen H. Heller, MD, I have contributed to the efficacy section of their Citizen's Petition for the professional labeling of aspirin to prevent a first MI.

I believe the case has become sufficiently strong for FDA action. You may recall that in 1988 my Physician's Health Study (PHS) of 22,071 had the aspirin component terminated early based on the unanimous recommendation of the external Data and Safety Monitoring Board (DSMB). Their recommendation was due principally to the emergence of a statistically extreme ( $p$  less than 1 in 100,000) 44% reduction in a first MI among those assigned at random to aspirin. Our preliminary report was published in NEJM and, working with Richard Peto in Oxford, we coordinated the publication in the BMJ of the British Doctor's Trial (BDT) of 5039, which showed no significant benefit of aspirin on first MI. I had been the first project director of that trial and coauthored this paper but, more importantly, both Richard and I considered the BDT a pilot for the PHS. Unfortunately, these simultaneous publications led to substantial confusion since the two trials were misinterpreted as showing divergent and inconsistent results. To overcome this confusion, Richard and I, along with George Hutchison, Chair of the PHS DSMB and Richard Doll, published in NEJM a meta-analysis of the two trials. Considering the effect of aspirin on first nonfatal MI, the PHS showed a 42%(+/-9SE) reduction ( $p$  less than 1 in 100,000) and the BDT showed a 3%(+/-19SE) non-significant reduction. Due to the far larger sample size of the PHS an overview or meta-analysis demonstrated a 33%(+/-9SE) reduction ( $p$  less than 2 in 100,000). In 1989, following publication of the

final report of the PHS in NEJM and an extensive FDA on-site audit which occurred over several weeks, my colleagues and I presented to the Cardiorenal Drug Advisory Committee (CRDAC) of FDA on behalf of Bristol-Myers Squibb, who had supplied the aspirin and placebo as well as packaging for the NIH funded PHS.

All six members of CRDAC who participated in the deliberations voted to professionally label aspirin to prevent a first MI, and the two who had only read the preliminary materials and voted in absentia voted against, so the final vote was 6-2. The FDA did not accept the recommendation of the CRDAC. Since that time, three additional large-scale primary prevention trials, Thrombosis Prevention Trial (TPT), Hypertension Optimal Treatment Study (HOT), and Primary Prevention Project (PPP) have been published, and all show significant benefits of aspirin. Subsequent to the publication of TPT and HOT, but before publication of the PPP, I had published a meta-analysis demonstrating significant benefits of aspirin of about 32% (p less than 1 in 100,000) on first MI and 13% (p less than 1 in 100) on all important vascular events. After publication of PPP, the US Preventive Services Task Force as well as American Heart Association have recommended aspirin prophylaxis for all men and women whose 10 year risks of a first cardiovascular event are 6% or greater and 10% or greater, respectively. Since the publication of PPP, my colleagues and I have an update on aspirin in the primary prevention of cardiovascular diseases, which is in press in the Archives of Internal Medicine.

Following several informal and productive discussions with Ray Lipicky, you, Bob Temple, and Charlie Ganley over the last year, it is my impression that you have secured both the PHS audit as well as the HOT database to guide you in your final decision. I would like to emphasize that Bayer has chosen to use my updated meta-analysis as the basis for their efficacy section as well as to support the more conservative AHA position to further enhance the positive benefit to risk ratio.

In conclusion, I believe that prompt action by FDA is both important and timely and has the potential for a substantial positive clinical and public health impact.

Please do not hesitate to contact me if you require further information.

With kindest personal regards.

Yours sincerely,



Charles H. Hennekens

cc Allen H. Heller, MD

## Table of Contents

	<b>PAGE</b>
<b>A. Action Requested</b>	<b>1</b>
<b>B. Statement of Grounds</b>	<b>2</b>
<b>1. Executive Summary</b>	<b>2</b>
<b>2. Introduction</b>	<b>3</b>
<b>3. Methods</b>	<b>5</b>
<b>4. Results</b>	<b>6</b>
<b>5. Conclusions</b>	<b>6</b>
<b>Summary Tables of the 5 Primary Prevention Trials</b>	
Physician's Health Study 1988-1989	<b>13</b>
British Doctor's Trial 1988	<b>15</b>
Thrombosis Prevention Trial 1998	<b>16</b>
Hypertension Optimal Treatment Trial 1998	<b>18</b>
Primary Prevention Project 2001	<b>20</b>
<b>6. Evaluation of Aspirin Safety</b>	<b>56</b>
General Overview	<b>56</b>
Safety in Primary Prevention Trials	<b>58</b>
<b>7. Risk/Benefit Evaluation</b>	<b>64</b>
<b>8. Regulatory Summary of Current Cardiovascular Aspirin Indications Approved in the U.S.</b>	<b>68</b>
<b>9. Aspirin Primary Prevention Indications Worldwide</b>	<b>70</b>
<b>10. Third Party Recommendations-Aspirin for Cardiovascular Primary Prevention</b>	<b>71</b>
American Diabetes Association (2003)	<b>73</b>
United States Preventive Services Task Force (2002)	<b>81</b>
American Heart Association (2002)	<b>94</b>
<b>11. Supporting Published Statements</b>	<b>102</b>
Augustovski F. Aspirin for Primary Prevention of Cardiovascular Events. 1998 Journal of General Internal Medicine	<b>103</b>
Assmann G., Coronary Heart Disease: Reducing the Risk A Worldwide View. 1999 Circulation	<b>116</b>
Cairns J. Antithrombotic Agents in Coronary Artery Disease. 1998 Chest	<b>126</b>
Colwell J. Aspirin Therapy in Diabetes. 1997 Diabetes Care	<b>150</b>
Eidelman R. An Update on Aspirin in the Primary Prevention of Cardiovascular Disease. 2003 Archives of Internal Medicine IN PRESS	<b>156</b>
Hebert P. An Overview of the 4 Randomized Trials of Aspirin Therapy in the Primary Prevention of Vascular Disease. Archives Internal Med Nov 2000	<b>157</b>
Hennekens C. Aspirin as a Therapeutic Agent in Cardiovascular Disease, A Statement for Healthcare Professionals from the American Heart Association. Circulation 1997	<b>163</b>

Lauer, M. Aspirin for Primary Prevention of Coronary Events. NEJM 2002	167
Mehta P., Aspirin in the Prophylaxis of Coronary Artery Disease. September 2002 Current Opinion in Cardiology	183
Passa P., Reducing the Cardiovascular Consequences of Diabetes Mellitus. 1998 Diabetes Medicine	191
Patrono C. Platelet Active Drugs the Relationship Among Dose, Effectiveness and Side Effects. 1998 Chest	196
Sanmuganathan P.S. Aspirin for Primary Prevention of Coronary Heart Disease: Safety and Absolute Benefit Related to Coronary Risk Derived from Meta-Analysis of Randomized Trials. Heart 2001	216
<b>12. Proposed Labeling</b>	<b>224</b>
<b>13. References</b>	<b>225</b>
<b>C. Environmental Impact</b>	<b>229</b>
<b>D. Economic Impact</b>	<b>230</b>
<b>E. Certification</b>	<b>231</b>

### Guide to Tables

<b>TABLE</b>	<b>TITLE</b>	<b>PAGE</b>
<b>1</b>	Features of the 5 Randomized Trials of Aspirin in the Primary Prevention of Cardiovascular Disease	<b>9</b>
<b>2</b>	Nonfatal Myocardial Infarction (MIs) and Nonfatal Stroke in the 5 Randomized Trials of Aspirin in the Primary Prevention of Cardiovascular Disease	<b>10</b>
<b>3</b>	Ischemic Versus Hemorrhagic Stroke (Fatal and Nonfatal) in the 5 Randomized Trials of Aspirin in the Primary Prevention of Cardiovascular Disease	<b>11</b>
<b>4</b>	Any Important Vascular Event and Vascular Death in the 5 Randomized Trials of Aspirin in the Primary Prevention of Cardiovascular Disease	<b>12</b>
<b>5</b>	Physicians' Health Study Study Report	<b>13</b>
<b>6</b>	British Doctor's Trial Study Report	<b>15</b>
<b>7</b>	Thrombosis Prevention Trial Study Report	<b>16</b>
<b>8</b>	HOT Trial Study Report	<b>18</b>
<b>9</b>	Primary Prevention Project Study Report	<b>20</b>
<b>10</b>	Five Primary Prevention Trials	<b>58</b>
<b>11</b>	Hemorrhagic Stroke / Intracranial Hemorrhage in Primary Prevention Trials	<b>61</b>
<b>12</b>	Major Gastrointestinal Events in Primary Prevention Trials	<b>62</b>